📣 VC round data is live. Check it out!

Guardant Health Valuation Multiples

Discover Guardant Health's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Hologic, Exact Sciences, United Imaging, Labcorp and more.

Guardant Health Overview

About Guardant Health

Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.


Founded

2011

HQ

United States

Employees

2.5K

Financials (LTM)

Revenue: $1B
EBITDA: ($203M)

EV

$18B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Guardant Health Financials

Guardant Health reported last 12-month revenue of $1B and negative EBITDA of ($203M).

In the same LTM period, Guardant Health generated $727M in gross profit, ($203M) in EBITDA losses, and had net loss of ($387M).

Revenue (LTM)


Guardant Health P&L

In the most recent fiscal year, Guardant Health reported revenue of $982M and EBITDA of ($222M).

Guardant Health is unprofitable as of last fiscal year, with gross margin of 64%, EBITDA margin of (23%), and net margin of (42%).

See analyst estimates for Guardant Health
LTMLast FY202320242025202620272028
Revenue$1B$982M$564M$739M$982M
Gross Profit$727M$633M$337M$449M$633M
Gross Margin65%64%60%61%64%
EBITDA($203M)($222M)($433M)($390M)($374M)
EBITDA Margin(18%)(23%)(77%)(53%)(38%)
EBIT Margin(22%)(26%)(100%)(60%)(45%)
Net Profit($387M)($416M)($479M)($436M)($416M)
Net Margin(34%)(42%)(85%)(59%)(42%)
Net Debt-$1B---

Financial data powered by Morningstar, Inc.

Guardant Health Stock Performance

Guardant Health has current market cap of $17B, and enterprise value of $18B.

Market Cap Evolution


Guardant Health's stock price is $129.18.

Guardant Health share price decreased by 0.5% in the last 30 days, and increased by 148.2% in the last year.

Guardant Health has an EPS (earnings per share) of $-3.14.

See more trading valuation data for Guardant Health
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$18B$17B-0.5%-0.5%39.9%148.2%$-3.14

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Guardant Health Valuation Multiples

Guardant Health trades at 15.8x EV/Revenue multiple, and (87.5x) EV/EBITDA.

See NTM and 2027E valuation multiples for Guardant Health

EV / Revenue (LTM)


Guardant Health Financial Valuation Multiples

As of June 2, 2026, Guardant Health has market cap of $17B and EV of $18B.

Guardant Health has a P/E ratio of (44.3x).

LTMLast FY202320242025202620272028
EV/Revenue15.8x18.1x31.4x24.0x18.1x
EV/EBITDA(87.5x)(79.9x)(40.9x)(45.5x)(47.4x)
EV/EBIT(73.5x)(68.4x)(31.4x)(40.0x)(40.6x)
EV/Gross Profit24.4x28.0x52.6x39.5x28.0x
P/E(44.3x)(41.1x)(35.7x)(39.3x)(41.1x)
EV/FCF(69.5x)(76.1x)(51.3x)(64.5x)(76.1x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Guardant Health Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Guardant Health Margins & Growth Rates

Guardant Health grew revenue by 34% but EBITDA decreased by 21% in the last fiscal year.

In the most recent fiscal year, Guardant Health reported gross margin of 64%, EBITDA margin of (23%), and net margin of (42%).

See estimated margins and future growth rates for Guardant Health

Guardant Health Margins

Last FY202420252026202720282029
Gross Margin64%61%64%64%
EBITDA Margin(23%)(53%)(38%)(13%)
EBIT Margin(26%)(60%)(45%)(16%)
Net Margin(42%)(59%)(42%)(26%)
FCF Margin(24%)(37%)(24%)(20%)

Guardant Health Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth34%31%33%34%
Gross Profit Growth34%33%41%34%
EBITDA Growth(21%)(10%)(4%)(53%)
EBIT Growth(17%)(21%)(1%)(51%)
Net Profit Growth(17%)(9%)(5%)(17%)
FCF Growth14%(20%)(15%)14%

Data powered by FactSet, Inc. and Morningstar, Inc.

Guardant Health Operational KPIs

Guardant Health's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.4M for the same period.

Guardant Health's Rule of 40 is 20% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Guardant Health's Rule of X is 71% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Guardant Health
LTMLast FY202320242025202620272028
Rule of 4013%20%---
Bessemer Rule of X60%71%---
Revenue per Employee-$0.4M---
Opex per Employee-$0.4M---
S&M Expenses to Revenue48%50%52%49%50%
G&A Expenses to Revenue16%22%28%24%22%
R&D Expenses to Revenue30%37%65%47%37%
Opex to Revenue-109%160%121%109%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Guardant Health Competitors

Guardant Health competitors include Hologic, Exact Sciences, United Imaging, Labcorp, Quest Diagnostics, Revvity, Pro Medicus, bioMérieux, Illumina and Qiagen.

Most Guardant Health public comparables operate across Medical Imaging & Diagnostics, Diagnostics & Genomics, BioTech, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Hologic----
Exact Sciences----
United Imaging6.5x6.0x35.1x34.3x
Labcorp2.0x1.9x11.4x11.1x
Quest Diagnostics2.5x2.4x12.5x12.2x
Revvity4.8x4.8x16.2x15.8x
Pro Medicus69.8x58.5x90.2x64.2x
bioMérieux2.1x2.1x8.6x8.6x

This data is available for Pro users. Sign up to see all Guardant Health competitors and their valuation data.

Start Free Trial

Guardant Health VC Funding History

Before going public, Guardant Health raised $550M in total equity funding, across 5 rounds.


Guardant Health Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
May-17Series E8VC; C.M. Capital Advisors; Khosla Ventures; Lightspeed Venture Partners; OrbiMed; Sequoia Capital; SoftBank Group; T. Rowe Price; Temasek Holdings$360M-Guardant Health is a precision oncology company offering liquid biopsy tests like Guardant360 and GuardantOMNI for cancer diagnostics, treatment selection, and biopharmaceutical research. The company, founded in 2011 and headquartered in Palo Alto, California, focuses on non-invasive cancer testing through blood samples to identify tumor mutations and guide therapy. In 2017, around the time of the $360 million Series C funding round led by SoftBank Vision Fund with participation from 8VC, C.M. Capital Advisors, Khosla Ventures, Lightspeed Venture Partners, OrbiMed, Sequoia Capital, T. Rowe Price, and Temasek Holdings, Guardant Health reported full-year revenue of $49.84 million, up 97.40% from $25.25 million in 2016. This growth was driven by precision oncology revenue from increased clinical and biopharmaceutical testing volumes. The 2017 funding round provided capital to scale operations, expand test adoption, and advance R&D. Revenue in 2017 reflected strong traction with 29,592 clinical tests and 10,370 biopharmaceutical tests performed in 2018, indicating momentum from the prior year. Gross profit for 2017 was $18.2 million with a 36.6% margin, while operating expenses reached $94.8 million amid investments in growth. The company went public in 2018 (NYSE: GH) following this round, with revenue accelerating to $90.64 million in 2018 (82% growth) and further to $214.38 million in 2019. Recent financials show 2024 annual revenue at $739.02 million, highlighting sustained scaling in the competitive liquid biopsy market against players like Foundation Medicine and Natera.
Jan-16Series DFelicis; Formation 8; Heritage Group; Hone Capital; Khosla Ventures; Laszlo Bock; Lightspeed Venture Partners; OrbiMed; Pear VC; Sequoia Capital$100M-Guardant Health, a Redwood City, CA-based precision oncology company founded in 2012, develops non-invasive liquid biopsy blood tests like Guardant360 for detecting genomic alterations in advanced cancer patients, enabling therapy selection without invasive tissue biopsies. The Series D round, announced January 7, 2016, and referenced as early 2016, raised approximately $100 million led by OrbiMed, with participation from Khosla Ventures, Sequoia Capital, Lightspeed Venture Partners, Formation 8 (predecessor to 8VC), Heritage Group, Pear VC, Pejman Mar, Hone Capital, and others including Laszlo Bock. The funding included equity and a term loan facility to expand the Guardant360 platform's technical and commercial reach, accelerate adoption among oncologists, enhance education efforts, and develop new products addressing the full cancer care continuum, including potential early detection and recurrence monitoring. At the time, Guardant Health reported running about 20,000 Guardant360 tests annually, a tenfold increase since the prior round, with nearly 2,000 cancer doctors using the test and plans to target the remaining U.S. oncologists. The company, CLIA-regulated with FDA-quality standards, focused on clinical validation through studies comparing to tissue biopsies and partnerships like with Flatiron Health for data analytics integrating test results with treatment outcomes. This Series D followed prior funding totaling around $500 million by IPO time, preceding a $360 million round in May 2017 led by SoftBank. Guardant Health went public in 2018 with a $238 million IPO, listing SoftBank, Sequoia, Khosla, and Lightspeed as major shareholders post-IPO, confirming the investor lineup matches the described round.
Feb-15Series CFelicis; Formation 8; Khosla Ventures; Lightspeed Venture Partners; Ling Wong; Sequoia Capital; SGH CAPITAL$50M-Guardant Health announced its Series C financing on February 3, 2015, raising $50 million led by Lightspeed Venture Partners with participation from Formation 8 and existing investors Khosla Ventures and Sequoia Capital. The company was founded in 2011 by serial entrepreneurs with expertise in next-generation sequencing and cancer diagnostics. Guardant Health developed Guardant360, described as the first and only comprehensive biopsy-free cancer blood test that identifies critical tumor genomic alterations in real-time, requiring only a simple blood draw instead of invasive tissue biopsies. This Series C funding brought the company's total funding to just under $100 million. The company planned to use the proceeds to expand availability of its Guardant360 product and invest in acceleration of its product roadmap to advance its vision of transforming cancer into a manageable disease. Guardant Health subsequently completed an IPO in October 2018.
Apr-14Series BKhosla Ventures; Ling Wong; Pear VC; Sequoia Capital; Signatures Capital$30M-Guardant Health is a cancer diagnostics company founded in 2012 that develops liquid biopsy tests to detect and monitor cancer using blood samples. The company's flagship product, Guardant360, uses circulating tumor DNA sequencing to analyze how tumors respond to cancer therapy. On April 22, 2014, Guardant Health closed a Series B financing round of $30-31.5 million led by Khosla Ventures, with participation from existing investor Sequoia Capital and new investors Pejman Mar Ventures, Pear Ventures, and others. Samir Kaul of Khosla Ventures joined the company's board as part of the transaction. The proceeds were intended to support Guardant's ambition to sequence cancer patients and develop early-detection capabilities. By 2017, Guardant Health had raised over $500 million in total funding across multiple rounds, demonstrating strong investor confidence in the liquid biopsy market and the company's technology platform.
Feb-14Series ACota Capital; Farzad Nazem; Frank Malek; OUP (Osage University Partners); Sequoia Capital$10M-Guardant Health, a Redwood City, California-based startup, develops non-invasive blood tests for cancer diagnostics, including the Guardant360 test that uses next-generation sequencing on blood samples to detect tumor mutations and guide treatment without biopsies. The company emerged from stealth mode in early 2014, announcing a $10 million funding round on February 11, 2014, led by Sequoia Capital with participation from Cota Capital, Farzad Nazem, Frank Malek, and Osage University Partners. This Series A round supported the commercial launch of Guardant360, described as the first blood-based diagnostic for real-time cancer monitoring. Clinical studies in U.S. cancer centers for breast, lung, colorectal, skin, and prostate cancers demonstrated that Guardant360 detected nearly 90% of tumor mutations in blood samples from 250 patients, enabling personalized treatment adjustments. The test received state and federal approvals and was adopted by leading cancer centers. Guardant Health's founders leveraged expertise in digital signal processing, next-generation sequencing, and rare genomics to build technology adaptable to sequencing advances.

Acquisitions by Guardant Health

Guardant Health has acquired 1 company to date.

Last acquisition by Guardant Health was on March 28th 2019. Guardant Health acquired Bellwether Bio for $30M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Guardant Health

Bellwether Bio
Description
Bellwether Bio is a biotechnology company developing cell-free DNA diagnostic technologies for oncology and other applications. Its platforms enable non-invasive liquid biopsies for early detection and monitoring.
HQ CountryUnited States
HQ City
Seattle, WA
Deal Date28 Mar 2019
Valuation$30M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Guardant Health acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by Guardant Health

Guardant Health has invested in 1 company to date.

Latest investment by Guardant Health was on July 19th 2021. Guardant Health invested in Lunit in their $26M Series C round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Guardant Health

Lunit
Description
Lunit Inc is a medical AI software company devoted to providing AI-powered total cancer care. Its products comprise of Lunit INSIGHT CXR, AI solution for Chest x-ray; Lunit INSIGHT MMG, AI solution for Mammography; Lunit SCOPE IO, AI-Powered Biomarker for Immuno-Oncology; and Lunit SCOPE PD-L1, AI Solution for PD-L1 Expression.
HQ CountrySouth Korea
HQ City
-
Deal Date19 Jul 2021
RoundSeries C
Raised$26M
InvestorsGuardant Health
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Guardant Health investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Guardant Health

When was Guardant Health founded?Guardant Health was founded in 2011.
Where is Guardant Health headquartered?Guardant Health is headquartered in United States.
How many employees does Guardant Health have?As of today, Guardant Health has over 2K employees.
Who is the CEO of Guardant Health?Guardant Health's CEO is Helmy Eltoukhy.
Is Guardant Health publicly listed?Yes, Guardant Health is a public company listed on Nasdaq.
What is the stock symbol of Guardant Health?Guardant Health trades under GH ticker.
When did Guardant Health go public?Guardant Health went public in 2018.
Who are competitors of Guardant Health?Guardant Health main competitors include Hologic, Exact Sciences, United Imaging, Labcorp, Quest Diagnostics, Revvity, Pro Medicus, bioMérieux, Illumina, Qiagen.
What is the current market cap of Guardant Health?Guardant Health's current market cap is $17B.
What is the current revenue of Guardant Health?Guardant Health's last 12 months revenue is $1B.
What is the current revenue growth of Guardant Health?Guardant Health revenue growth (NTM/LTM) is 31%.
What is the current EV/Revenue multiple of Guardant Health?Current revenue multiple of Guardant Health is 15.8x.
Is Guardant Health profitable?No, Guardant Health is not profitable.
What is the current EBITDA of Guardant Health?Guardant Health has negative EBITDA and is not profitable.
What is Guardant Health's EBITDA margin?Guardant Health's last 12 months EBITDA margin is (18%).
What is the current EV/EBITDA multiple of Guardant Health?Current EBITDA multiple of Guardant Health is (87.5x).
What is the current FCF of Guardant Health?Guardant Health's last 12 months FCF is ($255M).
What is Guardant Health's FCF margin?Guardant Health's last 12 months FCF margin is (23%).
What is the current EV/FCF multiple of Guardant Health?Current FCF multiple of Guardant Health is (69.5x).
How many companies Guardant Health has acquired to date?As of June 2026, Guardant Health has acquired 1 company.
What was the largest acquisition by Guardant Health?$30M acquisition of Bellwether Bio on 28th March 2019 was the largest M&A Guardant Health has done to date.
What companies Guardant Health acquired?Guardant Health acquired Bellwether Bio.
In how many companies Guardant Health has invested to date?As of June 2026, Guardant Health has invested in 1 company.
What was the last Guardant Health investment?On 19th July 2021 Guardant Health invested in Lunit, participating in a $26M Series C round.
In what companies Guardant Health invested in?Guardant Health invested in Lunit.

See public comps similar to Guardant Health

Lists including Guardant Health

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial